High levels of CD38 have been described on a subpopulation of peripheral CD4+CD25+CD127dim regulatory T cells, which are sensitive to therapeutic intervention with the CD38-specific monoclonal antibody daratumumab in individuals with multiple myeloma [41]. The gene discussed is CD4; the disease is plasma cell myeloma.